NOW LET US – AI RAG SaaS Studio TP.HCM
NOW LET US
Digital Product Studio
Back to news
DEV-TOOLS...4 min read

We're Pausing Asimov Press

Share
NOW LET US Article – We're Pausing Asimov Press

Asimov Press is going on hiatus starting April 2025. After a successful run featuring deep scientific reporting and innovative publishing projects, the founders are pausing operations to pursue new ventures.

That’s All, for Now

We're pausing Asimov Press.

Asimov Press is going on hiatus. While a few more articles will appear over the next month — and our stunning hardcover book, Making the Modern Laboratory, will come out this summer — operations will pause in April. All articles will remain freely accessible online.

As we prepare to pause, I want to celebrate what we’ve accomplished. In June 2023, Asimov Press was just a vague idea. (I remember posting the announcement from my phone in the Amsterdam metro, feeling a deep sense of fear about what we were starting.) A few months later, I brought on Xander Balwit. The two of us were its only editors and only full-time staff. We launched with about 7,000 subscribers, ported over from my personal blog, Codon. Our first article appeared in January 2024.

While I had attended journalism school and thought I knew about publishing, I soon discovered that literally everything — from managing people, to recruiting and paying writers, to fact-checking stories, printing books, and much else — doesn’t play out as it’s taught in school. By trial and error, Xander and I had to learn how to develop an eye for writers with exceptional promise, separate good pitches from vague ones, figure out which parts of a draft were most compelling, and make sure stories were told deeply enough to satisfy scientists, while remaining accessible to all “ambitious” readers.

Devon Balwit served as Copy Editor, helping us to convey these complex ideas in readable prose. In 2025, we hired Ella Watkins-Dulaney as our Art Director, and she promptly improved our header images and style. In the last several months, she has stepped into other roles as well, helping fact-check and compile the latest book. Ulkar Aghayeva composed and recorded the music for our podcasts, and also wrote several excellent articles for our pages. We’re also immensely grateful to the dozens of fact-checkers, artists, proofreaders, and writers who have contributed to maintaining a high bar of excellence at Asimov Press.

We’ve come a long way since our inception. Today, we have about 42,000 subscribers between Substack and our website. The press has published 149 original articles, reaching about half a million readers each month.

These articles have ranged from short to long, and from technical reports to history to speculative fiction. Some personal favorites have been The Penicillin Myth, about how Alexander Fleming’s discovery story may have been partly fabricated, How Nature Became a ‘Prestige’ Journal, What Makes an Experiment Beautiful?, and The Making of a Gene Circuit.

While many of our pieces were widely discussed, a handful made an even more tangible impact in the world. Our two recent essays on clinical trials — Clinic-in-the-Loop and AI Won’t Automatically Accelerate Clinical Trials — have been widely discussed in policy circles, as has the essay on China’s Clinical Trial Boom. The essay Mitochondria Are Alive became a bit of a rallying cry for funders considering new tools to engineer these organelles. An essay on artemisinin’s discovery was cited in discussions that led to the Research Revival Fund, a new nonprofit seeking to restore “neglected, illegible, or prematurely dismissed research.”

The Press has published and sold out of two anthologies. When we first tried our hand at printing books, we assumed we would lose a lot of money as printing is expensive, and around 96 percent of all books sell fewer than 1,000 copies. But in both cases, we sold thousands of copies, recouped our costs, and donated the profit to charities. I’m especially proud of our second book, the first commercially available book published in both print and DNA. It was mentioned in The New Yorker and featured in WIRED magazine. Thanks again to the companies that made it possible.

Our decision to pause is not related to funding. Asimov has supported us for the last two years, and we’ve received generous grants from Astera Institute and Stripe. But new projects have called away Xander and I, making it a good time to recalibrate.

For me, the greatest part of writing and editing is drawing closer to ideas and the people who generate them. Essays are a forcing function toward both. Great writers often find an exciting idea and decide to pursue it, only to confront a gap that nothing on the internet can fill — a question too deep or too specific to answer alone. And so the work begins: emailing and calling people, visiting where they work, hosting dinners, and sometimes flying around the world to understand it. The search for great ideas, and a deep understanding of them, is why I’ll keep writing, and helping others do so, for the rest of my life.

When Asimov Press reemerges, I know that those who lead it will be just as curious about the history and future of science as we have been. Thank you for taking this journey with us.

Until next time,

— Niko

© 2026 Now Let Us. All rights reserved.

Source: Hacker News

Advertisement
Ad slot ready: 5887729102

More in this category

NOW LET US Related – GLM 5.2 Is Out

dev-tools

GLM 5.2 Is Out

Zhipu AI has officially released GLM-5.2, its most powerful open-source model to date, featuring a 1M context window and advanced long-horizon task capabilities. The release underscores Zhipu's commitment to open-source AI and global scientific collaboration amid rising technological restrictions.

NOW LET US Related – Noise infusion banned from statistical products published by Census Bureau

dev-tools

Noise infusion banned from statistical products published by Census Bureau

The U.S. Department of Commerce has banned "noise infusion" from statistical products published by the Census Bureau, a decision that could have severe consequences for both data utility and privacy protection.

NOW LET US Related – Treating pancreatic tumours may have revealed cancer's master switch

dev-tools

Treating pancreatic tumours may have revealed cancer's master switch

A promising new drug called daraxonrasib has shown breakthrough results in treating pancreatic cancer, doubling median survival times. This achievement could pave the way for an entirely new class of cancer treatments.

NOW LET US Related – Every Frame Perfect

dev-tools

Every Frame Perfect

In UI design, perfection isn't just about the start and end states, but every single transition frame in between. Polishing these micro-interactions is key to building user trust.

NOW LET US Related – Leaving Mozilla

dev-tools

Leaving Mozilla

A poignant and candid reflection from a 15-year Mozilla veteran upon their departure. The author highlights the leadership's missteps in trying to emulate tech giants and urges Mozilla to return to its core values: community and uniqueness.

NOW LET US Related – Shepherd's Dog: A Game by the Most Dangerous AI Model

dev-tools

Shepherd's Dog: A Game by the Most Dangerous AI Model

A developer tested Anthropic's latest, supposedly 'too dangerous' AI model by asking it to build a long-held game idea in a single shot. The model succeeded, generating a complete 2,319-line game after a 45-minute reasoning session.

EXPLORE TOPICS

Discover All Categories

Deep dive into the specific technology sectors that matter most to you.